|
|
Vol. 9.21 – 17 June, 2024
|
|
|
|
|
|
|
|
Male and female control or tripartite motif containing 35 (TRIM35) overexpression adolescent and adult transgenic mice were used for all in vivo experiments. [Circulation]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
|
|
Scientists conducted real-time measurements of intracellular adenosine triphosphate concentration ([ATP]i) in ventricular myocytes using a genetically encoded ATP fluorescent reporter. Their data revealed rapid beat-to-beat variations in [ATP]i.
[Proceedings of The National Academy of Sciences of The United States of America]
|
|
|
|
|
|
|
|
Researchers used several computational analyses including single-cell RNAseq to show that muscle stem cells expressed low levels of canonical endothelial cell markers in mice.
[eLife]
|
|
|
|
|
|
Investigators generated a double-transgenic mouse model that allowed tamoxifen-inducible heme oxygenase-1 expression in Pax7 positive cells of dystrophic muscles.
[Skeletal Muscle]
|
|
|
|
|
|
|
|
PAI-039, a specific inhibitor of plasminogen activator inhibitor-1 (PAI-1), and small interfering RNA were used to inhibit PAI-1 expression in cultured human smooth muscle cells.
[Arteriosclerosis Thrombosis and Vascular Biology]
|
|
|
|
|
|
Researchers tested if myocardin-related transcription factors suppressed inflammation also by targeting cGAS-STING signaling. Interrogation of a transcriptomic dataset where myocardin was overexpressed using a panel of 56 cGAS-STING cytokines showed the panel to be repressed.
[Scientific Reports]
|
|
|
|
|
|
The cytotoxicity of corilagin was assessed using the CCK8 assay. Mouse vascular smooth muscle cells, pre-incubated with oxidized low-density lipoprotein, underwent treatment with varying concentrations of corilagin. [International Journal of Immunopathology and Pharmacology]
|
|
|
|
|
|
|
|
The authors summarize the current knowledge about circRNA origin, conservation, characteristics and function and discuss bioinformatics and wet-lab methods used in circRNA research. [British Journal of Pharmacology]
|
|
|
|
|
|
|
|
Cranbury Pharmaceuticals announced the US FDA approved the Abbreviated New Drug Application for the first generic version of Emflaza® oral suspension (deflazacort) for the treatment of Duchenne muscular dystrophy. The generic deflazacort oral suspension is now available to patients in the United States. [Tris Pharma]
|
|
|
|
|
|
|
|
July 7 – 11, 2024 Saint Paul, Minnesota, United States
|
|
|
|
|
|
|
|
|
|
|
Indiana University – Indianapolis, Indiana, United States
|
|
|
|
|
|
|
KU Leuven – Leuven, Belgium
|
|
|
|
|
|
|
|
|
European Molecular Biology Laboratory (EMBL) – Grenoble, France
|
|
|
|
|
|
|
University of Pittsburgh – Pittsburgh, Pennsylvania, United States
|
|
|
|
|
|